These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3149210)

  • 41. [Daily fluctuations of plasma diphenylhydantoin in patients treated with diphenylhydantoin and sodium valproate].
    Pisani F; Di Perri R
    Acta Neurol (Napoli); 1981 Feb; 3(1):61-3. PubMed ID: 6787844
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
    Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
    Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
    Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
    Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valproic acid and risperidone.
    van Wattum PJ
    J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):866-7. PubMed ID: 11501681
    [No Abstract]   [Full Text] [Related]  

  • 48. Valproic acid for Kleine-Levin syndrome.
    Crumley FE
    J Am Acad Child Adolesc Psychiatry; 1997 Jul; 36(7):868-9. PubMed ID: 9204661
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of dimethylsulfoxide pretreatment on valproic acid pharmacokinetics in rat.
    Runci F; Bianchi E; Giorgi G; Micheli L
    Riv Eur Sci Med Farmacol; 1988 Feb; 10(1):11-6. PubMed ID: 3152741
    [No Abstract]   [Full Text] [Related]  

  • 50. Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.
    Sherr JD; Kelly DL
    Psychiatr Serv; 1998 Oct; 49(10):1355-7. PubMed ID: 9779912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium.
    Dutta S; Reed RC
    Am J Health Syst Pharm; 2006 May; 63(10):904-6. PubMed ID: 16675645
    [No Abstract]   [Full Text] [Related]  

  • 52. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
    Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration.
    Gordon JD; Riggs KW; Rurak DW; Kwan E; Hall C; Abbott FS
    Drug Metab Dispos; 1995 Dec; 23(12):1383-9. PubMed ID: 8689948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.
    Battino D; Estienne M; Avanzini G
    Clin Pharmacokinet; 1995 Oct; 29(4):257-86. PubMed ID: 8549027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disposition and protein binding of valproic acid in the developing rat.
    Haberer LJ; Pollack GM
    Drug Metab Dispos; 1994; 22(1):113-9. PubMed ID: 8149869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of valproic acid in patients with bipolar disorder.
    Vasudev K; Das S; Goswami U; Tayal G
    J Psychopharmacol; 2001 Sep; 15(3):187-90. PubMed ID: 11565626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronopharmacology in Therapeutic Drug Monitoring-Dependencies between the Rhythmics of Pharmacokinetic Processes and Drug Concentration in Blood.
    Dobrek L
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diurnal variation in pharmacokinetics of valproic acid with unequal dosing intervals.
    Johno I; Nakamura T; Horiuchi T; Nadai M; Kitazawa S; Yoshimine N; Kuzuya F
    Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2551-6. PubMed ID: 3149210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.